Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells

Annals of Hematology

Volumn 91, Issue 12, 2012, Pages 1861-1870

  Tsao, Twee ^a   Shi, Yuexi ^a   Kornblau, Steven ^a   Lu, Hongbo ^a   Konoplev, Sergej ^a   Antony, Ansu ^a   Ruvolo, Vivian ^a   Qiu, Yi Hua ^a   Zhang, Ninaxiang ^a   Coombes, Kevin R ^a   Andreeff, Michael ^a   Kojima, Kensuke ^a   Konopleva, Marina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

5 azacytidine; ABT 737; AML; BCL 2; MCL 1; P53

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; AZACITIDINE; DNA METHYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AZACITIDINE; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; DNA MODIFICATION METHYLASES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MITOCHONDRIA; NEOPLASM PROTEINS; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871015322     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1537-8     Document Type: Article

References (31)

1. Yip KW, Reed JC (2008) Bcl-2 family proteins and cancer. Oncogene 27:6398-6406
2. Kornblau SM, Vu HT, Ruvolo P et al (2000) BAX and PKC? modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res 6:1401-1409
3. Oltersdorf T, Elmore SW, Shoemaker AR et al (2005) An inhibitor of BCL-2 family proteins induces regression of solid tumours. Nature 435:677-681
4. Konopleva M, Contractor R, Tsao T et al (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375-388
5. Roberts AW, Seymour JF, Brown JR et al (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30:488-496
6. Adams JM (2012) Therapeutic potential of a peptide targeting BCL-2 cell guardians in cancer. J Clin Invest 122:1965-1967
7. Rice KL, Hormaeche I, Licht JD (2007) Epigenetic regulation of normal and malignant hematopoiesis. Oncogene 26:6697-6714
8. Silverman LR, Demakos EP, Peterson BL et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429-2440
9. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562-569
10. Soriano AO, Yang H, Faderl S et al (2007) Safety and clinical activity of the combination of 5-AZAytidine, valproic acid, and alltrans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302-2308
11. Kojima K, Konopleva M, Samudio IJ et al (2005) MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106:3150-3159
12. Petitjean A, Mathe E, Kato S et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629
13. Kojima K, Shimanuki M, Shikami M et al (2008) The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 22:1728-1736
14. Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M (2012) Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. Cancer 118:1023-1031
15. Grimwade D (2007) Impact of cytogenetics on clinical outcome in AML. In: Karp JE (ed) Acute myeloid leukemia. Humana, Totowa, pp 177-192
16. Kojima K, McQueen T, Chen Y et al (2011) p53 activation of mesenchymal stromal cells partially abrogates microenvironmentmediated resistance to FLT3 inhibition in AML through HIF-1?- mediated down-regulation of CXCL12. Blood 118:4431-4439
17. Kornblau SM, Qiu YH, Zhang N et al (2011) Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia. Blood 118:5604-5612
18. Tibes R, Qiu YH, Lu Y et al (2006) Reverse phase protein array (RPPA): validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoetic stem cells (HSC). Mol Cancer Ther 5:2512-2521
19. Kornblau SM, Tibes R, Qiu YH et al (2009) Functional proteomic profiling of AML predicts response and survival. Blood 113:154-164
20. Hunyady B, Krempels K, Harta G, Mezey E (1996) Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. J Histochem Cytochem 44:1353-1362
21. Hu J, He X, Baggerly KA et al (2007) Non-parametric quantification of protein lysate arrays. Bioinformatics 23:1986-1994
22. Neeley ES, Kornblau SM, Coombes KR, Baggerly KA (2009) Variable slope normalization of reverse phase protein arrays. Bioinformatics 25:1384-1389
23. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-681
24. Kiziltepe T, Hideshima T, Catley L et al (2007) 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 6:1718-1727
25. van Delft MF, Wei AH, Mason KD et al (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399
26. Chen S, Dai Y, Harada H, Dent P, Grant S (2007) Mcl-1 downregulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67:782-791
27. Traina F, Jankowska AM, Visconte V et al. (2011) Impact of molecular mutations on treatment response to hypomethylating agents in MDS [abstract 461]. Blood 118
28. Walker AR, Metzeler KH, Geyer S (2011) Impact of DNMT3A mutations on clinical response to the hypomethylating agent decitabine in older patients (pts) with acute myeloid leukemia (AML) [abstract 944]. Blood 118
29. Khan R, Schmidt-Mende J, Karimi M et al (2008) Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol 36:149-157
30. Bogenberger JM, Shi C-X, Gonzales G et al. (2011) RNAi screening identifies BCL-XL as an erythroid lineage-specific 5- Azacytidine sensitizer while the BCL-2/BCL-XL/BCL-W inhibitor ABT-737 results in more universal sensitization in leukemia cells [abstract 3513]. Blood 118
31. Rücker FG, Schlenk RF, Bullinger L et al (2012) TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 119:2114-2121